Monthly ranibizumab for nonproliferative macular telangiectasia type 2: A 12-month prospective study

American Journal of Ophthalmology

Volumn 151, Issue 5, 2011, Pages 876-886.e1

  Charbel Issa, Peter ^a,b   Finger, Robert P ^a   Kruse, Kathrin ^a   Baumller, Snke ^a   Scholl, Hendrik P N ^a,c   Holz, Frank G ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERVENTION STUDY; NONPROLIFERATIVE MACULAR TELANGIECTASIA TYPE 2; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA FLUORESCEIN ANGIOGRAPHY; RETINA MACULOPATHY; RETINA THICKNESS; THICKNESS; VISUAL ACUITY;

EID: 79955122042     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.11.019     Document Type: Article

References (52)

1. J.D. Gass, and B.A. Blodi Idiopathic juxtafoveolar retinal telangiectasis Update of classification and follow-up study Ophthalmology 100 10 1993 1536 1546 (Pubitemid 23292864)
2. P. Charbel Issa, H.P.N. Scholl, H.M. Helb, and F.G. Holz Idiopathic macular telangiectasia F.G. Holz, R.F. Spaide, Medical Retina 2007 Springer Berlin, Heidelberg 183 197
3. T.E. Clemons, M.C. Gillies, and E.Y. Chew Baseline characteristics of participants in the natural history study of macular telangiectasia (MacTel) MacTel Project Report No 2 Ophthalmic Epidemiol 17 1 2010 66 73
4. P. Charbel Issa, F.G. Holz, and H.P.N. Scholl Metamorphopsia in patients with macular telangiectasia type 2 Doc Ophthalmol 119 2 2009 133 140
5. R.P. Finger, P. Charbel Issa, R. Fimmers, F.G. Holz, G.S. Rubin, and H.P.N. Scholl Reading performance is reduced due to parafoveal scotomas in patients with macular telangiectasia type 2 Invest Ophthalmol Vis Sci 50 3 2009 1366 1370
6. T.E. Clemons, M.C. Gillies, and E.Y. Chew The National Eye Institute Visual Function Questionnaire in the Macular Telangiectasia (MacTel) Project Invest Ophthalmol VisSci 49 10 2008 4340 4346
7. L.A. Paunescu, T.H. Ko, and J.S. Duker Idiopathic juxtafoveal retinal telangiectasis: new findings by ultrahigh-resolution optical coherence tomography Ophthalmology 113 1 2006 48 57 (Pubitemid 43021727)
8. A. Gaudric, G. Ducos de Lahitte, S.Y. Cohen, P. Massin, and B. Haouchine Optical coherence tomography in group 2A idiopathic juxtafoveolar retinal telangiectasis Arch Ophthalmol 124 10 2006 1410 1419 (Pubitemid 44537141)
9. S.M. Cohen, M.L. Cohen, F. El-Jabali, and S.E. Pautler Optical coherence tomography findings in nonproliferative group 2A idiopathic juxtafoveal retinal telangiectasis Retina 27 1 2007 59 66 (Pubitemid 46095832)
10. P. Charbel Issa, H.M. Helb, F.G. Holz, H.P.N. Scholl MacTel Study Group Correlation of macular function with retinal thickness in nonproliferative type 2 idiopathic macular telangiectasia Am J Ophthalmol 245 1 2008 169 175
11. P. Charbel Issa, F.G. Holz, and H.P.N. Scholl Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia Ophthalmology 114 9 2007 1736 1742 (Pubitemid 47332685)
12. P. Charbel Issa, T.T. Berendschot, G. Staurenghi, F.G. Holz, and H.P. Scholl Confocal blue reflectance imaging in type 2 idiopathic macular telangiectasia Invest Ophthalmol Vis Sci 49 3 2008 1172 1177
13. P. Charbel Issa, R.L.P. van der Veen, A. Stifjs, F.G. Holz, H.P.N. Scholl, and T.T.J.M. Berendschot Quantification of reduced macular pigment optical density in the central retina in macular telangiectasia type 2 Exp Eye Res 89 1 2009 25 31
14. P. Charbel Issa, R.P. Finger, F.G. Holz, H.M. Helb, and H.P.N. Scholl A new diagnostic approach in patients with type 2 macular telangiectasia: confocal reflectance imaging Acta Ophthalmol Scand 86 4 2008 464 465
15. H.M. Helb, P. Charbel Issa, R.L.P. van der Veen, T.T.J.M. Berendschot, H.P.N. Scholl, and F.G. Holz Macular pigment density and distribution in patients with type II macular telangiectasia Retina 28 6 2008 808 816
16. P. Charbel Issa, H.P. Scholl, and A. Gaudric Macular full-thickness and lamellar holes in association with type 2 idiopathic macular telangiectasia Eye 23 2 2009 435 441
17. R. Klein, B.A. Blodi, S.M. Meuer, C.E. Myers, E.Y. Chew, and B.E.K. Klein The prevalence of macular telangiectasia type 2 in the Beaver Dam Eye Study Am J Ophthalmol 150 1 2010 55 62
18. M.C. Gillies, M. Zhu, and E.Y. Chew Familial asymptomatic macular telangiectasia type 2 Ophthalmology 116 12 2009 2422 2429
19. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 4 2004 581 611 (Pubitemid 39099316)
20. A.P. Adamis, and D.T. Shima The role of vascular endothelial growth factor in ocular health and disease Retina 25 2 2005 111 118 (Pubitemid 40365933)
21. E. Chew Parafoveal telangiectasis S.J. Ryan, Retina 2006 Elsevier Mosby Philadelphia 1409 1415
22. P. Charbel Issa, R.P. Finger, F.G. Holz, and H.P.N. Scholl Eighteen-month follow-up of intravitreal bevacizumab in type 2 idiopathic macular telangiectasia Br J Ophthalmol 92 7 2008 941 945 (Pubitemid 351969675)
23. M.A. Gamulescu, A. Walter, H. Sachs, and H. Helbig Bevacizumab in the treatment of idiopathic macular telangiectasia Graefes Arch Clin Exp Ophthalmol 246 8 2008 1189 1193
24. J.L. Kovach, and P.J. Rosenfeld Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II Retina 29 1 2009 27 32
25. P.J. Rosenfeld, D.M. Brown, and J.S. Heier Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1419 1431 (Pubitemid 44511557)
26. D.M. Brown, P.K. Kaiser, and M. Michels Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 14 2006 1432 1444 (Pubitemid 44511558)
27. G.B. Jaissle, P. Szurman, and K.U. Bartz-Schmidt [Recommendation for the implementation of intravitreal injections - statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA)] [Article in German] Klin Monbl Augenheilkd 222 5 2005 390 395 (Pubitemid 40825853)
28. H.M. Helb, P. Charbel Issa, and M. Fleckenstein Clinical evaluation of simultaneous confocal scanning laser ophthalmoscopy imaging combined with high-resolution spectral-domain optical coherence tomography Acta Ophthalmol 88 8 2010 842 849
29. P. Charbel Issa, H.M. Helb, K. Rohrschneider, F.G. Holz, and H.P.N. Scholl Microperimetric assessment of patients with type II macular telangiectasia Invest Ophthalmol Vis Sci 48 8 2007 3788 3795 (Pubitemid 351261119)
30. P. Charbel Issa, E. Trger, R.P. Finger, F.G. Holz, R. Wilke, and H.P. Scholl Structure-function correlation of the human central retina PLoS One 5 9 2010 e12864
31. S. Schmitz-Valckenberg, K. Fan, and A. Nugent Correlation of functional impairment and morphological alterations in patients with group 2A idiopathic juxtafoveal retinal telangiectasia Arch Ophthalmol 126 3 2008 330 335 (Pubitemid 351398455)
32. P. Charbel Issa, F.G. Holz, and H.P. Scholl The article by Kovach and Rosenfeld Retina 29 5 2009 717 718
33. H.G. Blaauwgeers, G.M. Holtkamp, and H. Rutten Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris Evidence for a trophic paracrine relation Am J Pathol 155 2 1999 421 428 (Pubitemid 29370392)
34. M. Saint-Geniez, A.S. Maharaj, and T.E. Walshe Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors PLoS One 3 11 2008 e3554
35. K. Nishijima, Y.S. Ng, and L. Zhong Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury Am J Pathol 171 1 2007 53 67 (Pubitemid 47339226)
36. I. Kim, A.M. Ryan, and R. Rohan Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes Invest Ophthalmol Vis Sci 40 9 1999 2115 2121 (Pubitemid 29365177)
37. M.B. Powner, M.C. Gillies, and M. Tretiach Perifoveal Mller cell depletion in a case of macular telangiectasia type 2 Ophthalmology 117 12 2010 2407 2416
38. U.E. Wolf-Schnurrbusch, L. Ceklic, and C.K. Brinkmann Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments Invest Ophthalmol Vis Sci 50 7 2009 3432 3437
39. R.C. Watzke, M.L. Klein, and J.C. Folk Long-term juxtafoveal retinal telangiectasia Retina 25 6 2005 727 735 (Pubitemid 41254542)
40. D.W. Park, H. Schatz, H.R. McDonald, and R.N. Johnson Grid laser photocoagulation for macular edema in bilateral juxtafoveal telangiectasis Ophthalmology 104 11 1997 1838 1846 (Pubitemid 28100339)
41. G.D. De Lahitte, S.Y. Cohen, and A. Gaudric Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization Am J Ophthalmol 138 5 2004 892 894 (Pubitemid 39452955)
42. M. Cakir, Z. Kapran, D. Basar, C.A. Utine, F. Eroglu, and I. Perente Optical coherence tomography evaluation of macular edema after intravitreal triamcinolone acetonide in patients with parafoveal telangiectasis Eur J Ophthalmol 16 5 2006 711 717 (Pubitemid 44870753)
43. Y. Matsumoto, and M. Yuzawa Intravitreal bevacizumab therapy for idiopathic macular telangiectasia Jpn J Ophthalmol 54 4 2010 320 324
44. B.M. Stoffelns, K. Schoepfer, and C. Kramann [Idiopathic macular telangiectasia-follow-up with and without laser photocoagulation] [Article in German] Klin Monbl Augenheilkd 227 4 2010 252 256
45. O.O. Maia Jr, M.T. Bonanomi, W.Y. Takahashi, V.P. Nascimento, and B.S. Takahashi Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia Am J Ophthalmol 144 2 2007 296 299 (Pubitemid 47094721)
46. R. Jorge, R.A. Costa, D. Calucci, and I.U. Scott Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis Graefes Arch Clin Exp Ophthalmol 245 7 2006 1045 1048
47. S. Mandal, P. Venkatesh, Z. Abbas, R. Vohra, and S. Garg Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia Graefes Arch Clin Exp Ophthalmol 245 12 2007 1825 1829 (Pubitemid 350154017)
48. M.P. Shanmugam, H.M. Mythri, and N.S. Shetty Intravitreal bevacizumab for parafoveal telangiectasia-associated choroidal neovascular membrane Indian J Ophthalmol 55 6 2007 490 491
49. L. Konstantinidis, I. Mantel, L. Zografos, and A. Ambresin Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia Graefes Arch Clin Exp Ophthalmol 247 11 2009 1567 1569
50. N. Mavrakanas, E. Mendrinos, C.J. Pournaras, and J. Salzmann Intravitreal ranibizumab and bevacizumab for bilateral subretinal neovascularization secondary to idiopathic juxtafoveal telangiectasia type 2A Acta Ophthalmol 87 8 2009 930 932
51. J. Ruys, J.J. De Laey, Y. Vanderhaeghen, and E.H. Van Aken Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane Eye (Lond) 21 11 2007 1433 1434 (Pubitemid 350066483)
52. R.P. Lira, V.B. Silva, T.M. Cavalcanti, A.C. de Souza, and A.P. Pinto Intravitreous ranibizumab as treatment for macular telangiectasia type 2 Arch Ophthalmol 128 8 2010 1075 1078